S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BCEL

Atreca (BCEL) Stock Price, News & Analysis

$0.08
-0.01 (-11.76%)
(As of 03/27/2024 ET)
Today's Range
$0.07
$0.09
50-Day Range
$0.06
$0.33
52-Week Range
$0.05
$1.35
Volume
322,044 shs
Average Volume
8.69 million shs
Market Capitalization
$2.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Atreca MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
14,233.3% Upside
$10.75 Price Target
Short Interest
Healthy
0.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.42mentions of Atreca in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.61) to ($0.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.57 out of 5 stars

BCEL stock logo

About Atreca Stock (NASDAQ:BCEL)

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

BCEL Stock Price History

BCEL Stock News Headlines

Atreca, Inc. (NASDAQ:BCEL) Short Interest Update
Atreca Inc. Cl A
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Atreca Stock (NASDAQ:BCEL), Short Interest Report
Immunome to buy assets from California biotech company
Atreca Inc.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Atreca Inc Class A BCEL
Atreca to Cut About 40% of Workforce
Atreca Inc (BCEL)
BAKER BROS. ADVISORS LP Reduces Stake in Atreca Inc
What's Going On With Atreca Inc Stock?
Stifel Downgrades Atreca Inc - (BCEL)
Stifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)
Atreca (BCEL) Gets a Buy from H.C. Wainwright
See More Headlines
Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.75
High Stock Price Target
$25.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+14,233.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-97,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.01 per share

Miscellaneous

Free Float
35,146,000
Market Cap
$2.97 million
Optionable
Optionable
Beta
1.17
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. John A. Orwin M.B.A. (Age 59)
    President, CEO, Director & Principal Financial Officer
    Comp: $927.03k
  • Dr. Tito A. Serafini Ph.D. (Age 61)
    Founder & Director
    Comp: $665.5k
  • Mr. Rick Ruiz (Age 60)
    Principal Accounting Officer
  • Ms. Courtney J. Phillips J.D. (Age 49)
    General Counsel & Corporate Secretary
  • Roger Richard Ruiz
    Vice President of Finance

BCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Atreca stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings
or view top-rated stocks.

What is Atreca's stock price target for 2024?

5 brokers have issued 12-month price objectives for Atreca's shares. Their BCEL share price targets range from $4.00 to $25.00. On average, they expect the company's stock price to reach $10.75 in the next year. This suggests a possible upside of 14,233.3% from the stock's current price.
View analysts price targets for BCEL
or view top-rated stocks among Wall Street analysts.

How have BCEL shares performed in 2024?

Atreca's stock was trading at $0.1320 at the beginning of the year. Since then, BCEL shares have decreased by 43.2% and is now trading at $0.0750.
View the best growth stocks for 2024 here
.

Are investors shorting Atreca?

Atreca saw a decline in short interest in March. As of March 15th, there was short interest totaling 148,000 shares, a decline of 45.7% from the February 29th total of 272,700 shares. Based on an average trading volume of 8,350,000 shares, the days-to-cover ratio is presently 0.0 days.
View Atreca's Short Interest
.

When is Atreca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our BCEL earnings forecast
.

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.74) EPS for the quarter, meeting analysts' consensus estimates of ($0.74).

What is John Orwin's approval rating as Atreca's CEO?

6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

What other stocks do shareholders of Atreca own?
When did Atreca IPO?

Atreca (BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Who are Atreca's major shareholders?

Atreca's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.30%), Vanguard Group Inc. (2.30%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, John A Orwin, Phillips Courtney and Tito Serafini.
View institutional ownership trends
.

How do I buy shares of Atreca?

Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners